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Inhibition of Human Melanoma Cell Growth
by the Dietary Flavonoid Fisetin Is Associated
with Disruption of Wnt/b-Catenin Signaling and
Decreased Mitf Levels
Deeba N. Syed1,2, Farrukh Afaq1,3, Nityanand Maddodi1, Jeremy J. Johnson1, Sami Sarfaraz1, Adeel Ahmad1,
Vijayasaradhi Setaluri1,2 and Hasan Mukhtar1,2
The prognosis of advanced melanoma remains poor in spite of treatment advances, emphasizing the
importance of additional preventive measures. Flavonoids, natural components of our diet, are being
investigated for their chemopreventive/therapeutic properties. Microphthalmia-associated transcription factor
(Mitf), downstream of the Wnt/b-catenin pathway, has become an important prognostic marker of melanoma.
In this study, we show that treatment of 451Lu melanoma cells with the dietary flavonoid fisetin (3,7,30,
40-tetrahydroxyflavone) resulted in decreased cell viability with G1-phase arrest and disruption of Wnt/b-catenin
signaling. This was accompanied by a decrease in the expression of Wnt protein and its co-receptors, as well as
by a parallel increase in the expression of endogenous Wnt inhibitors. Fisetin-treated cells showed increased
cytosolic levels of Axin and b-TrCP and decreased phosphorylation of glycogen synthase kinase 3b associated
with decreased b-catenin stabilization. Fisetin-mediated interference with the functional cooperation between
b-catenin and T-cell factor (TCF)-2 resulted in the downregulation of positively regulated TCF targets, such as
c-myc, Brn-2, and Mitf. Flow-cytometric analysis of Mitf-overexpressing cells showed that fisetin repressed
Mitf-induced cell proliferation. Finally, administration of fisetin to 451Lu-xenografted nude mice resulted in
the inhibition of tumor development and decreased Mitf expression. Our data suggest that fisetin can be
developed as an effective agent against melanoma because of its potential inhibitory effect on b-catenin/Mitf
signaling.
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INTRODUCTION
Constitutive activation of the Wnt signaling pathway is a
feature of a number of cancers including malignant melano-
ma with aberrant nuclear accumulation and subsequent
upregulation of b-catenin transcription response (Larue and
Delmas, 2006). Binding of Wnt to the transmembrane
Frizzled receptor prompts Dishevelled to prevent proteolytic
destruction of b-catenin. Stabilized b-catenin then transits
to the nucleus, where it converts transcriptional repressors
known as T-cell factors (TCFs) into activators and regulates
cell fate through gene expression (Bowerman, 2008). Micro-
phthalmia-associated transcription factor (Mitf) has been
shown to reside downstream of the canonical Wnt pathway
during melanocyte differentiation from pluripotent neural
crest cells. Although the expression of many melanocytic/
pigmentation markers is lost in human melanoma, Mitf
expression remains intact, even in non-pigmented tumors,
suggesting a role for Mitf beyond its role in differentiation
(Widlund et al., 2002). It has been suggested that Mitf can
redirect b-catenin transcriptional activity away from canoni-
cal Wnt signaling-regulated genes toward Mitf-specific
target promoters, thereby enhancing the repertoire of genes
regulated by b-catenin (Schepsky et al., 2006).
Epidemiological evidence suggests that a plant-based diet
rich in flavonoids is effective against cancer (Kundu and Surh,
2005; Khan et al., 2008). Thus, flavonoids have become not
only important potential chemopreventive agents but also
therapeutic natural agents. Fisetin (3,7,30,40-tetrahydroxyfla-
vone) belongs to the flavonol subgroup of flavonoids together
with quercetin, myricetin, and kaempferol, and is found in
many fruits and vegetables, such as strawberries, apples,
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persimmons, kiwi, onions, and cucumbers. Fisetin has been
shown to facilitate long-term memory potentiation and to
enhance object recognition in mice, and reduced behavioral
deficits following stroke in other animal models (Maher et al.,
2007). Emerging data from our laboratory and from that of
others suggest that fisetin in addition to its neuroprotective
effects possesses anti-cancer properties (Syed et al., 2008).
The aim of this study was to investigate whether fisetin can
inhibit the growth of highly aggressive human melanoma cells
and to define the molecular basis of this effect. In this study,
we determined that fisetin exerts its anti-proliferative actions
in human melanoma cells by interference with the key elements
of the Wnt pathway. In addition, we investigated the effect
of fisetin on cellular localization of b-catenin and studied the
impact of fisetin on TCF-2/LEF-1-regulated proteins with emphasis
on Mitf as a direct target of Wnt/b-catenin signaling.
RESULTS
Fisetin decreases the viability of 451Lu human melanoma cells
We evaluated the effect of fisetin on the growth of metastatic
451Lu human melanoma cells, which exhibit constitutive
Wnt signaling in addition to harboring a mutation in the B-Raf
gene (Maddodi et al., 2010; Tarapore et al., 2010). Fisetin
treatment of 451Lu cells at various time points displayed a
dose-dependent decrease in cell viability as analyzed by the
MTT (3-(4,5 dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
bromide) assay (Figure 1a). IC50 was estimated to be 80,
37.2, and 17.5 mM at 24, 48, and 72 hours, respectively.
These observations led to the selection of doses for further
mechanistic studies that ranged from 40 to 80 mM over
24 hours. The dose-dependent effect of fisetin on cellular
morphology after 24 hours treatment as observed by phase-
contrast microscopy can be visualized in Figure 1b. Relative
to 451Lu cells, normal human melanocytes were resistant to
fisetin-mediated growth repression (data not shown).
Fisetin induces G1-phase arrest in 451Lu human
melanoma cells
To examine the effect of fisetin on 451Lu cell cycle, flow-
cytometric analysis was performed, and the expression of cell
cycle-regulatory molecules was evaluated by western blot
analysis. Figure 1c shows that fisetin treatment arrested cells
in the G1 phase, with an increase in the mean percentage
(68.2 and 74.5% at 60 and 80mM, respectively) of cells in G1
as compared with 56.6% of cells in untreated control
samples. Furthermore, inhibition of cell-cycle progression
by fisetin correlated with a reduction in the protein levels of
cyclin-dependent kinases (cdks) -2, -4, and -6, key cell cycle-
regulatory proteins involved in the G1-phase progression
(Figure 1d).
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Figure 1. Effect of fisetin on melanoma cells. (a) 451Lu cells were treated with fisetin for 24, 48, and 72hours, and MTT assay was performed. Data expressed as
the percentage of cell viability represent mean±SE of three experiments. (b) Phase-contrast microscopy: representative pictures of 451Lu cells treated with
fisetin for 24 hours (bar¼50 mm). (c) Cells treated with fisetin were collected and stained with PI using the Apo-Direct kit. After FACS analysis, cellular DNA
histograms were analyzed by ModiFitLT V3.0. Data are representative of duplicate experiments. (d) Whole-cell lysates were analyzed by immunoblot analysis.
Equal loading was confirmed by reprobing for b-actin. Data shown are representative of three independent experiments. cdk, cyclin-dependent kinase;
FACS, fluorescence-activated cell sorting; IC50, half-maximal inhibitory concentration; MTT, 3-(4,5 dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide;
PI, propidium iodide.
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Downregulation of the Wnt protein and its co-receptors
by fisetin
To assess the functional relevance of Wnt/b-catenin signaling
in the context of cell-growth inhibition, we analyzed
the effect of fisetin on the Wnt protein and its co-receptors.
Figure 2a demonstrates that cells treated with increasing
doses of fisetin showed a dose-dependent decrease in the
expression of Wnt growth factor protein, Wnt5a. Interest-
ingly, downregulation of co-receptor (Frizzled/LRP6) expres-
sions along with a decrease in Dishevelled expression
coincided with an increase in endogenous Wnt inhibitors
(DKK1 and WIF) in fisetin-treated cells (Figure 2a and b).
Decrease in nuclear b-catenin levels by fisetin
Next, we examined the effect of fisetin on cellular localiza-
tion of b-catenin. Western blot analysis indicated that
b-catenin was mainly localized to the cytosolic compartment
of untreated cells, whereas increasing doses of fisetin were
associated with a decrease in cytosolic b-catenin with a
concomitant decrease in nuclear b-catenin (Figure 2c, top).
Immunofluorescence studies further elucidated this effect.
b-Catenin staining was notably reduced in the nuclei of
fisetin-treated melanoma cells, indicating that a significant
amount of b-catenin was phosphorylated and degraded
resulting in decreased nuclear accumulation (Figure 2c,
bottom).
We investigated whether the inhibitory effect of fisetin on
b-catenin expression extended to other melanoma cell lines.
For this, we selected two cell lines, WM35 and Mel928, with
increased b-catenin levels and performed MTT assay and
western blot analysis after exposing them to increasing doses
of fisetin. As shown in Figure 2d, fisetin treatment effectively
decreased b-catenin protein expression in both cell lines
accompanied by a dose-dependent inhibition in growth
and viability.
Stimulation of cytosolic degradation of b-catenin by fisetin
through modulation of destruction complex
From a mechanistic perspective, the effect of fisetin
on suppressing b-catenin expression might be facilitated by
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Figure 2. Effect of fisetin on the Wnt signaling pathway. (a, b) Whole-cell, (c, top) cytosolic, and nuclear lysates were analyzed by western blotting and equal
loading confirmed by b-actin and lamin; (c, bottom) 451Lu cells seeded on tissue culture slides and treated with/without fisetin, fixed in 2% paraformaldehyde,
and incubated with b-catenin anti-antibody were observed under a Zeiss-Axiophot microscope (bar¼ 6 mm). (d, top) Whole-cell lysates of WM35 and Mel928
melanoma cells were analyzed by western blot analysis and equal loading confirmed by b-actin; (middle) MTT assay performed on WM35 and Mel928
melanoma cells treated with fisetin for 24 hours. Data shown are representative of three independent experiments; (d, bottom) table showing mutations in cell
lines used. DVL, Dishevelled; FZD-1, Frizzled-1; MTT, 3-(4,5 dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide.
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two distinct mechanisms: augmenting the destruction com-
plex and increasing proteasomal degradation. Figure 3a
shows an increase in the expression levels of Axin and
b-TrCP proteins in the cytosol of fisetin-treated cells,
indicating a stimulatory effect of fisetin on destruction
complex proteins. To substantiate the involvement of Axin
in fisetin-mediated decrease in b-catenin levels, we used an
in vitro pull-down assay to assess the binding of Axin with
endogenous b-catenin in the lysates of fisetin-treated cells
(Figure 3b). 451Lu cells were treated with fisetin for 24 hours,
and cell lysates were incubated with agarose beads coated
with b-catenin antibody and subjected to western blotting.
As shown in Figure 3b, treatment of 451Lu cells with fisetin
significantly increased the amount of Axin associated with
the pull down.
The phosphorylation of b-catenin by glycogen synthase
kinase 3b (GSK3b) targets it for proteasomal degradation.
GSK3b activity, in turn, is regulated by its phosphorylation
status, with phosphorylation at Ser9 rendering the protein
functionally inactive. Figure 3a shows that fisetin treatment
resulted in decreased phosphorylation of GSK3b in a dose-
dependent manner. To establish whether fisetin-induced
suppression of b-catenin is mediated through a GSK3b-
dependent mechanism, we assessed the effect of fisetin on
b-catenin expression in combination with the known GSK3b
inhibitor, LiCl. Immunoblot analysis showed that LiCl could
protect 451Lu cells from fisetin-mediated suppression of
b-catenin expression (Figure 3c, top). As several structurally
diverse inhibitors of GSK3 must affect the given biological
process similarly before concluding that fisetin is acting
through inhibition of GSK3, we co-treated 451Lu cells with
fisetin and the highly selective GSK3b inhibitor, BIO, and
analyzed lysates for b-catenin protein levels. As before, fisetin
was unable to counteract BIO-facilitated activation of
b-catenin, indicating that GSK3b had a key role in fisetin-
induced b-catenin degradation (Figure 3c, middle).
b-TrCP is involved in fisetin-mediated b-catenin proteolysis
b-TrCP, the F-box protein in the E3 ubiquitin ligase complex,
binds and tags b-catenin for proteasomal degradation (Liu
et al., 2004). Fisetin treatment increased the expression of
b-TrCP in a dose-dependent manner parallel to that of
b-catenin repression, indicating a mechanistic link between
two diverse responses (Figure 3a). To further examine this, we
used MG-132 to block proteasome-mediated protein degra-
dation. Treatment with fisetin consistently induced a
decrease in b-catenin levels in 451Lu melanoma cells.
However, the effect of fisetin on the reduction of b-catenin
was abrogated by the addition of MG-132, indicating that
fisetin induces the degradation of b-catenin in a proteasome-
dependent manner (Figure 3c, bottom). Time-dependent
studies further verified the role of b-TrCP in the suppression
of b-catenin expression by fisetin (Figure 3d). Next, we
investigated whether fisetin promoted b-catenin degradation
by regulating b-TrCP gene expression or by increasing the
stability of the protein. Reverse transcription-PCR analysis
indicated that exposure of 451Lu cells to different doses of
fisetin did not affect the mRNA level of b-TrCP (data
not shown), despite a robust increase in its protein level
(Figure 3a and d). This finding suggested that the upregulation
of b-TrCP by fisetin was mediated by prolonging its protein
stability. To verify this, we assessed the effect of fisetin on the
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Figure 3. Fisetin regulates cellular b-catenin levels through modulation of the destruction complex. (a) Cytosolic fraction of fisetin-treated cells was analyzed
by western blotting and equal loading confirmed by b-actin. (b) Equal amounts of cell lysates treated with/without fisetin (60mM) were immunoprecipitated with
anti-b-catenin antibody, followed by western blot analysis with anti-Axin antibody or immunoblotted with anti-CKIa and b-actin antibodies (input, bottom).
(c) 451Lu cells co-treated with fisetin and GSK3b inhibitors LiCl (20mM), BIO (10 nM), or MG-132 (1 mM) for 24 hours, followed by western blot analysis. (d, left)
451Lu cells treated with/without 60 mM fisetin harvested at different time points were analyzed by western blotting; (d, right) 451Lu cells treated with/without
60mM fisetin and 50 mgml1 CHX, for different time intervals, followed by western blotting were analyzed for b-TrCP protein stability. Equal loading was
confirmed by b-actin. Data shown are representative of three independent experiments. CHX, cycloheximide; GSK3b, glycogen synthase kinase 3b.
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half-life of b-TrCP in 451Lu cells co-treated with fisetin and
the protein synthesis inhibitor, cycloheximide. In untreated
cells, b-TrCP had a half-life of B6 hours, whereas in
fisetin-treated cells, the protein level of b-TrCP remained
unaltered throughout the course of cycloheximide treatment
(Figure 3d).
Pleiotropic effects of fisetin on multiple b-catenin signaling
targets
We next examined the effect of fisetin on the cadherin
signaling network. As shown in Figure 4a, fisetin caused
differential repression of the cadherin family of proteins with
a decrease in N-cadherin and an increase in b-catenin’s
binding partner, E-cadherin. The upregulation of cadherin-
associated p120 catenin protein expression in fisetin-treated
cells reported to be significantly reduced in cancer tissues
was also noteworthy (Perez-Moreno and Fuchs, 2006).
Fisetin interferes with the functional cooperation between
TCF-2 and b-catenin
As b-catenin transactivates gene expression in a complex
with TCF proteins, we studied the effect of fisetin on the TCF
complex using mobility shift assay. Figure 4b (top) shows a
dose-dependent decrease of the TCF complex in fisetin-
treated 451Lu cells. We next examined the effect of fisetin
on different proteins of the TCF family. Fisetin caused a
differential repression of these proteins in the order of
TCF-24TCF-1 with minimal change in TCF-4 (Figure 4b,
bottom). We wanted to know whether fisetin-regulated
b-catenin-dependent control is mediated through its effect
on TCF-2–b-catenin interaction. Treatment of cells with
TCF-2-small-interfering RNA, but not with scrambled RNA,
resulted in a significant decrease in the protein expression of
b-catenin (Figure 4c, top). This decrease in b-catenin
expression was comparable with that observed in fisetin-
treated cells and was more pronounced when cells were
co-treated with TCF-2-small-interfering RNA and fisetin.
A pull-down assay with b-catenin further identified TCF-2
as the key regulator of b-catenin-mediated effects in fisetin-
treated cells (Figure 4c, bottom). We next studied the effect of
fisetin on the protein expression of known TCF-regulated
genes. Figure 4d shows that fisetin treatment resulted
in downregulated protein levels of positively regulated
b-catenin/TCF targets, such as c-myc, Brn2, and Mitf.
Suppression of proliferation by fisetin involves Mitf
We then examined the effect of fisetin on Mitf, critical in
melanoma cell proliferation. Reduced levels of Mitf protein
and mRNA in fisetin-treated cells suggested that fisetin-
induced Mitf repression was mediated at the transcriptional
level (Figure 5a). Furthermore, downregulated Mitf expres-
sion was accompanied by a decrease in the anti-apoptotic
Bcl-2 protein expression (data not shown). To examine
the involvement of Mitf in b-catenin’s mitogenic effect, we
overexpressed Mitf in 451Lu melanoma cells. Flow-cyto-
metric analysis revealed that the ectopic expression of Mitf
resulted in an increase in the S-phase fraction of the cell cycle
as compared with untreated control cells (39.5 vs. 34.5%),
whereas fisetin-treated cells showed a significant decrease in
S-phase content (10 vs. 34.5%), respectively. Moreover,
fisetin relieved cells from Mitf-induced cell proliferation
(18 vs. 39.5%) (Figure 5b and c).
Fisetin inhibits the growth of 451Lu human melanoma
cells and decreases Mitf levels in athymic mice
Although our in vitro data unambiguously demonstrated that
fisetin had potent growth-inhibitory activity, questions
remained regarding its in vivo efficacy. Athymic nude mice
were implanted with 451Lu melanoma cells and divided into
three cohorts, each with six animals that were administered
fisetin/vehicle intraperitoneally. The first group received the
vehicle (DMSO) only, whereas the second and the third
groups received fisetin 1 and 2mg per animal (45 and
90mgkg1 body weight), respectively. Fisetin was adminis-
tered twice weekly and seemed tolerable as depicted by body
weight measurements (Figure 6a). On day 7, the appearance
of small tumors was observed in the control cohorts, followed
by tumors in the fisetin-treated groups by day 14. A smaller
average tumor volume was consistently observed in mice
treated with fisetin. This was more marked in animals
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receiving 1mg fisetin than in animals receiving the 2mg
dose, indicating a non-linear dose response (Figure 6b and c).
In the control group, the average tumor volume of 788.5mm3
was reached at day 45, whereas mice receiving 1mg fisetin
had an average tumor volume of 263.8mm3 representing a
significant suppression in tumor growth by 66.6%
(P¼0.0012). The 2mg group, at the same time point had
an average tumor volume of 331mm3 and tumor suppression
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by B58.1% (P¼ 0.0007). A significant decrease in the
protein expression of Mitf, as well as downstream target
Bcl-2 and cdk-2 was observed in treated mice, indicating that
the growth-inhibitory effect of fisetin extended to the in vivo
situation (Figure 6d and e).
DISCUSSION
Malignant melanoma is a deadly human cancer with no
effective cure for metastatic disease. The aim of this study was
to identify natural compounds that may be used against
melanoma for chemopreventive/therapeutic purposes.
Not only does their use circumvent the need to introduce
foreign compounds into the human body but also natural
agents are expected, in general, to be less toxic, more
accessible, and less expensive than synthetic agents (Syed
et al., 2008). Strategies are being developed to limit
constitutive Wnt signaling involved in the genesis of a
number of malignancies, including melanoma (Takahashi-
Yanaga and Sasaguri, 2007). Fisetin-mediated decrease in the
expression of transmembrane receptors, Frizzled and LRP6,
as well as upregulation of the Axin protein indicates that
fisetin interferes with the interaction of LRP6, Axin, and
b-catenin (Figures 2 and 3). In addition, an increase in the
endogenous Wnt inhibitors DKK and WIF1 may also
contribute to suppress the canonical Wnt pathway in
fisetin-treated cells.
Activated Wnt signaling positively feeds into the phos-
phoinositide 3-kinase/Akt pathway through inhibition of
GSK3, a key component shared by both pathways (Fang
et al., 2007). Fisetin treatment resulted in dephosphorylating
activation of GSK3b (Figure 2). Moreover, fisetin suppressed
Akt activation in 451Lu melanoma cells through decreased
phosphorylation at both Ser473 and Thr308 residues (data
not shown). This is important as Akt is believed to act as a
molecular switch that increases angiogenesis and generation
of superoxide, fostering more aggressive behavior in mela-
noma tumors (Govindarajan et al., 2007).
Decreased HOS/b-TrCP-2 levels hinder the degradation of
b-catenin (Spiegelman et al., 2002). Fisetin and other dietary
flavonoids have been shown to enhance proteasome activity
and to promote nerve cell survival (Maher, 2008). This is
consistent with our data that indicate that fisetin increased
b-TrCP expression levels through protein stabilization, there-
by facilitating ubiquitin-dependent proteasomal degradation
of b-catenin (Figure 3). The ability of fisetin to target b-TRCP
further provides a molecular basis to account for its reported
effect on modulating the expression of cell cycle-regulatory
proteins (Lu et al., 2005).
The transcriptional activity of b-catenin through its
interaction with the TCF family is recognized as the major
effector of the Wnt signaling pathway, and its activation has
been associated with malignancy (Larue and Delmas, 2006).
Our data show that fisetin interferes with the b-catenin/TCF
axis through targeting the TCF-2/LEF-1 protein in 451Lu
melanoma cells (Figure 4). This effect of fisetin was specific
for melanoma cells when compared with other cancer cell
lines in which fisetin exerts its effect through targeting
TCF-4 (Syed et al., 2008). Analysis of protein expression of
fisetin-treated melanoma cells showed a dose-dependent
reduction in the levels of TCF targets involved in the
b-catenin signaling network, including ubiquitous genes such
as c-myc, cell lineage-restricted genes such as Brn2, and
melanocyte-specific genes such as Mitf (Figures 4 and 5). The
retention of Mitf expression in the vast majority of human
melanomas has led to its use as a diagnostic tool in this
malignancy. Suppression of melanoma clonogenic growth by
disruption of b-catenin-TCF-2 could be rescued by constitu-
tive Mitf (Widlund et al., 2002). In addition, reduction of
Mitf activity sensitizes melanoma cells to chemotherapeutic
agents. It is suggested that targeting Mitf in combination with
B-RAF or cdk inhibitors may offer a rational therapeutic
avenue into melanoma, a highly chemotherapy-resistant
neoplasm (Garraway et al., 2005). Our data showed that
fisetin, a known cdk inhibitor, was able to override the
proliferative effect of Mitf and thus induce growth repression
in human melanoma cells. The inhibitory effect of fisetin was
evident in tumor-xenografted mice as well. Treatment with
fisetin at two different doses significantly slowed the
progression of 451Lu tumor growth in nude mice as shown
in Figure 6. This inhibition of tumor growth was coupled with
a decrease in Mitf levels. Thus, it is conceivable that fisetin
can inhibit melanoma cell proliferation by targeting the Wnt/
b-catenin pathway and its downstream targets in conjunction
with its direct effect on the cdk–cyclin network. It will be of
interest to determine whether other Mitf-regulated genes can
be targeted by fisetin to modulate the mitogenic response.
Using dose scaling as advised in the Food and Drug
Administration guidelines, the human equivalent dose of
fisetin in our in vivo study translated toB97mg of fisetin in a
60-kg adult and represents a reasonable starting point for
future clinical investigations.
In summary, our goal in this study was to gain a
mechanistic understanding of the mode of action of
fisetin in melanoma cells. Our in vitro studies showed
that a decrease in b-catenin levels, induction of b-TrCP,
and a reduction of Mitf mRNA and protein levels are
possible criteria for fisetin-mediated suppression of Wnt
signaling in melanoma cells (Figure 6). Importantly, this
was reflected in our in vivo studies that showed signifi-
cant growth inhibition in mice implanted with melanoma
xenografts and decreased Mitf levels upon treatment with
fisetin with two different doses. In contemplating future
applications, there is strong evidence that this compound
may be a strong candidate in cancer prevention and
therapeutic strategies.
MATERIALS AND METHODS
Materials
Fisetin, LiCl, C2211 (MG-132), and cycloheximide were purchased
from Sigma Chemical (St Louis, MO). BIO was obtained from
Calbiochem (Gibbstown, NJ).
Antibodies
Antibodies were obtained from Cell Signaling Technology (Beverly,
MA). Frizzled, WIF1, b-TrCP, and Mitf antibodies were purchased
from Santa Cruz Biotechnology (Santa Cruz, CA).
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Cell culture/treatment
Mel 928 (ATCC, Manassas, VA), WM35, and 451Lu human melanoma
cell lines kindly provided by Dr Meenhard Herlyn (Wistar Institute,
Philadelphia, PA) were cultured in MEM obtained from Gibco
(Carlsbad, CA), with 10% fetal bovine serum and 1% penicillin–-
streptomycin, at 37 1C with 5% CO2 in a humid environment. For
dose/time-dependent studies, cells (70% confluent) were treated
with fisetin dissolved in DMSO (20–80mM) for 24 hours at 37 1C
in media and harvested for further studies. For time-dependent
studies, cells treated with 60 mM fisetin were harvested at the
specified time points.
Cell viability
Cell viability was determined by MTT assay as described previously
(Johnson et al., 2008).
Cell-cycle analysis and apoptosis
451Lu cells treated with/without fisetin for 24 hours were processed
for labeling with fluorescein-tagged dUTP nucleotide and propidium
iodide using the Apo-Direct kit (Phoenix Flow Systems, San Diego,
CA) and analyzed using ModiFitLT V3.0. (Verily Software House,
Topsham, ME) software.
Preparation of cell lysates
After fisetin treatment, whole, cytosolic, and nuclear lysates were
prepared, and western blot analysis performed as described
previously (Syed et al., 2007).
Immunochemistry
Immunocytochemical analysis of 451Lu cells, seeded in tissue
culture slides treated with/without fisetin was performed as
described earlier (Syed et al., 2007). Tumor tissues collected from
mice fixed in 10% formalin were blocked (5% goat serum/
phosphate-buffered saline) for 30minutes after deparaffinization
and rehydration in xylene and graded series of ethanol. After
incubation with Mitf- and horseradish peroxidase-conjugated
secondary antibodies, slides were counterstained with hematoxylin
and immunoreactive complexes detected using 3,30-diaminobenzi-
dene (Dako, Carpinteria, CA). Sections were visualized on a Zeiss-
Axiophot DMHT microscope (Jena, Germany) and images captured
using a camera attached to computer. Figures were composed using
Adobe Photoshop 7.0 (Adobe Systems, Mountain View, CA).
Transient transfection and RNA interference
Transfection of cells was performed by electroporation using an
Amaxa Nucleofector according to the manufacturer’s protocol (Amaxa
Biosystems, Lonza , Allendale, NJ) with the pCMV5a-Mitf plasmid and
a corresponding vector control pCMV5a plasmid/small-interfering
RNA against TCF-2 with scrambled small-interfering RNA as control
(Santa Cruz Biotechnology). Transfected cells were harvested 24hours
after fisetin treatment for immunoblot/flow-cytometric analysis.
Electrophoretic mobility shift assay
Electrophoretic mobility shift assay for TCF was performed using
lightshift chemiluminiscent electrophoretic mobility shift assay
kit (Pierce, Rockford, IL) as per the manufacturer’s protocol. In
brief, double-stranded TCF oligonucleotide 50-AGTTGAGGGG
ACTTTCCCAGGC-30; 30-TCAACTCCCCTGAAAGGGTCCG-50 was
labeled using the Biotin 30-end labeling kit as described previously
(Syed et al., 2007).
Xenograft studies
Athymic (nu/nu) female nude mice (NxGen Biosciences, San Diego,
CA) were housed under pathogen-free conditions, in the University
of Wisconsin Animal Resource Facility, with a 12-hour light/12-hour
dark schedule and fed an autoclaved diet ad libitum. Overall,
1 106 451Lu cells suspended in Matrigel were injected subcuta-
neously into each flank of 18 mice randomly divided into 3 groups.
The first and the second groups received an intraperitoneal injection
of fisetin (1 and 2mg per animal, respectively) dissolved in DMSO,
biweekly, whereas the third group (DMSO only) served as the control
group. Mice weight and tumor volumes were recorded. After 45 days,
mice were killed and tumor tissues harvested. All animal experiments
were approved by and carried out according to IACUC guidelines.
Statistical analysis
Results were analyzed using a two-tailed Student’s paired t-test,
using GraphPad QuickCalcs software (GraphPad Software, La Jolla,
CA); Po0.05 was considered statistically significant.
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